The regulatory setback occurred on July 24, 2026, when the Committee for Medicinal Products for Human Use issued a negative opinion regarding the marketing authorization for the neurodegenerative treatment. Investors responded immediately, driving the share price down by $2.995 to close at $9.525.

Legal representatives at Pomerantz LLP are now examining whether company leadership engaged in unlawful business practices or failed to uphold fiduciary duties leading up to the announcement. The firm, which maintains offices in New York, Chicago, London, and other global hubs, is inviting affected shareholders to provide details regarding their holdings and potential participation in a class action suit.